Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

Elastic (NYSE:ESTC – Free Report) had its price objective lifted by Canaccord Genuity Group from $130.00 to $135.00 in a ...

Fintel reports that on February 28, 2025, Canaccord Genuity downgraded their outlook for ICF International (NasdaqGS:ICFI) ...

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a ...

Canaccord Genuity Sustainability Virtual Summit February 26, 2025 2:20 PM ETCompany ParticipantsRyan Corbett - Chief ...

will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor ...

Uncertainty around North American trade has hindered capital-markets activity and stalled investments in Canada, according to Canaccord Genuity Group Inc. Chief Executive Officer Daniel Daviau ...